Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Biocon Limited ( (IN:BIOCON) ) just unveiled an announcement.
Biocon Limited has disclosed that India Ratings & Research, acting as the monitoring agency, has issued reports on the utilisation of proceeds from its Qualified Institutions Placement for the quarter ended March 31, 2026. The reports, dated May 7, 2026, have been reviewed and noted by the company’s Audit Committee and Board of Directors and are available on Biocon’s website, signalling continued regulatory compliance and transparency in capital deployment.
The filing, made to both BSE and NSE under applicable SEBI regulations, underscores Biocon’s adherence to disclosure norms governing the use of capital raised from institutional investors. By formally placing the monitoring report on record and highlighting board-level oversight, the company aims to reassure stakeholders about the governance of its fundraising activities and the proper tracking of funds utilisation.
More about Biocon Limited
Biocon Limited is an India-based biopharmaceutical company headquartered in Bengaluru, operating in the pharmaceuticals and life sciences industry. The company focuses on developing and manufacturing biologics, biosimilars, and other specialty pharmaceuticals for global markets, and its shares are listed on both BSE and the National Stock Exchange of India.
Average Trading Volume: 216,783
Technical Sentiment Signal: Buy
Current Market Cap: 616.6B INR
For detailed information about BIOCON stock, go to TipRanks’ Stock Analysis page.